Companies · Pharmaceuticals
MILWAUKIE · Pharmaceuticals
Diligence memoA one-page analyst read on THC Pharmaceutical — recommendation, valuation, rhythm, risks.→THC Pharmaceutical looks under-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
THC Pharmaceutical is one of 1613 Pharmaceuticals companies tracked from MILWAUKIE. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 52% of sector peers (real $). Modeled value above 26% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $9.0M | — | $40.9M | $18.9M | 90% |
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
THC Pharmaceutical is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| AJNA BioSciences PBC | Pharmaceuticals | Series A | $9.0M | $11.3M | same sector · same stage |
| Intezyne Technologies, Inc. | Pharmaceuticals | Series A | $9.3M | $14.9M | same sector · same stage |
| Insigna, Inc. | Pharmaceuticals | Series A | $8.5M | $16.0M | same sector · same stage |
| Modulo Bio, Inc. | Pharmaceuticals | Series A | $9.8M | $25.7M | same sector · same stage |
| Invirsa, Inc. | Pharmaceuticals | Series A | $9.8M | $9.2M | same sector · same stage |
| CURE PHARMACEUTICAL Corp | Pharmaceuticals | Series A | $9.9M | $10.0M | same sector · same stage |
| Avicanna Inc. | Pharmaceuticals | Series A | $9.9M | $24.3M | same sector · same stage |
| Slate Medicines, Inc. | Pharmaceuticals | Series A | $10.0M | $24.8M | same sector · same stage |
See where THC Pharmaceutical sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at THC Pharmaceutical, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.